厄贝沙坦联合胺碘酮治疗阵发性房颤的临床观察

Clinical Observation of Irbesartan and Amiodarone Joint Treatment in Paroxysmal Atrial Fibrillation

目的探讨厄贝沙坦联合胺碘酮治疗阵发性房颤的临床效果及安全性。方法将我院阵发性房颤患者60例随机分为观察组和对照组,对照组给予胺碘酮治疗,观察组给予厄贝沙坦联合胺碘酮治疗,评估临床效果。结果治疗后观察组左房内径明显低于对照组,观察组左房内径明显低于治疗前,两者比较差异具有统计学意义(P<0.05)。治疗后7d观察组转复窦性心律明显高于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后12个月观察组维持窦性心律明显高于对照组,两组比较差异具有统计学意义(P<0.05)。两组均未出现明显的药物治疗副反应。结论厄贝沙坦联合胺碘酮治疗阵发性房颤效果好,副作用少,值得应用。

Objective To investigate the effect and safety of conbined treatment of irbesartan and amiodarone in paroxysmal atrial fibrillation. Methods 60 cases with paroxysmal atrial fibrillation were divided into observation group and control group. The control group received the amiodarone, while the observation group received the combined treatment of irbesartan and amiodarone. Results The left atrial diameter of the observation group after treatment was fewer than those of the control group, and the left atrial diameter of the observation group after treatment was fewer than those before treatment （P 0.05）. The recovery rate of sinus rhythm of the observation group in 7 days after treatment was higher than those of the control group （P 0.05）. The maintain rate of sinus rhythm of the observation group in 12 months after treatment was higher than those of the control group （P 0.05）. There was no significant difference in untoward reaction in the two groups （P 0.05）. Conclusion Irbesartan and amiodarone joint treatment in paroxysmal atrial fibrillation has a good effect and lower side effect, which deserves clinical application.